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2 
Abstract 35 
Objective: We challenge epidemiologic knowledge regarding ovarian carcinoma (OC) by 36 
bridging the gap between clinical and autopsy data. 37 
Methods: Autopsy reports, histological slides and clinical files from 660 patients in whom OC 38 
was diagnosed from 1975-2005 were studied (autopsy cohort, n=233; Clinical Cancer Registry 39 
from the local gyneco-oncologic center, n=427). 40 
Results: Out of the autopsy cohort, we identified four distinct subgroups of patients: 1) OC was 41 
diagnosed before autopsy, n=156 (67.0%). 2) OC was an incidental finding, n=16 (6.8%). 3) 42 
The ovarian tumors were not primary OC but rather metastases from other primary tumors; this 43 
revised diagnosis was first made by using current histopathological knowledge/techniques, n=24 44 
(10.3%). 4) Death was directly due to OC in its final stage and OC was first diagnosed by 45 
autopsy, n=37 (15.9%); when these cases were added to the Clinical Cancer Registry to an 46 
adjusted OC incidence model, the autopsy cases comprised 8.8% of the adjusted cohort and 47 
almost doubled the percentage of oldest patients (≥80 years at diagnosis) from 4.9% to 9.3% 48 
(p=0.013).  49 
Conclusions: Epidemiological data from the 1970s-1990s may overestimate true incidence 50 
because up to 10% of carcinomas in the ovary were not properly classified. Patients who were 51 
first diagnosed with OC by autopsy comprise a distinct subgroup. These are patients who have 52 
not been seen by specialized oncologists and thus play no role in their perception of the disease. 53 
Nevertheless, these cases have impact on prevalence and incidence data of OC and in an era of 54 
reduced autopsy rates will probably be overlooked. 55 
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Introduction 59 
In developed countries, ovarian carcinoma (OC) is the fifth most frequent cause of cancer death 60 
in women and the most lethal gynecologic malignancy [1]. In most cases, the disease is 61 
diagnosed in its late stage. Despite current multimodal therapies, most patients cannot be cured. 62 
According to WHO estimates in 2012, there are approximately 239,000 new cases annually 63 
worldwide, and about 152,000 patients die of the disease [2].  64 
The epidemiologic knowledge regarding the incidence of OC stems predominantly from 65 
epidemiological, population-based cancer registries whose aim is to identify all cases from a 66 
well-defined regional population, including clinically symptomatic cases as well as autopsy-67 
only detected incidental cases. Histologic verification is considered the gold standard to ensure 68 
valid and accurate diagnoses of cancer registry data. In the pre-immunohistochemical era, 69 
histopathologic interpretation in cases with suspected OC, especially in case of peritoneal 70 
carcinomatosis, was not always unequivocal as other cancers may present a histologic 71 
phenotype similar to OC [3-6]. Thus it might be speculated that a substantial proportion of 72 
patients might be either falsely assigned as OC (false positive) or true, clinically relevant cases 73 
(false negative) may have been missed in the past, thereby introducing bias in long-term trends 74 
in OC. In order to get a gross estimate of the suspected bias, we reviewed autopsy reports and 75 
clinical records from all cases of OC from 1975-2005 and re-evaluated past histolopathologic 76 
diagnoses with current immunohistochemical methods. The few studies, which analyzed 77 
autopsy data in OC, evaluated exclusively the metastatic patterns of the disease at the time of 78 
death [7-12]. To our knowledge, this is the first study which challenges current epidemiologic 79 
knowledge regarding OC by bridging the gap between clinical and autopsy data. 80 
 81 
Patients and Methods 82 
Between 1975 and 2005, 22,023 female autopsies were performed at the Institute of Pathology 83 
of the University of Basel, Switzerland. Of these, primary OC was diagnosed in 233 cases. In 84 
4 
order to avoid heterogeneity, only epithelial tumors, which comprise 90% of all ovarian cancers 85 
[13], were considered in the study. Borderline tumors were excluded from analysis. 86 
The autopsy reports and clinical records of these 233 patients, including surgical reports and 87 
information on chemotherapy treatment, were reviewed for the following information: date of 88 
diagnosis, patient’s age at diagnosis, clinical course (including information regarding surgery 89 
and chemotherapy), age at death, cause of death, disease-specific survival time (DSS), and 90 
patterns of metastatic sites at time of autopsy. The median age of all cases was 70 years (range: 91 
24-98 years). Median DSS was five months (range: 0 to 300 months). 92 
To confirm the histological findings reported in the autopsies, approximately 4,550 microscopic 93 
sections were reviewed by a specialized gynecopathologist (G.S.), averaging 20 sections/case. 94 
In cases in which the diagnosis primary OC questionable due to histomorphological features, 95 
immunohistochemical tests (antibodies against CDX2, CK7, CK8/18, CK19, CK20, CEA, 96 
estrogen receptor, progesterone receptor, WT1, p16 and p53) were performed. 97 
In addition to the autopsy data, we also reviewed the clinical data of 427 patients who were 98 
diagnosed and treated for OC in the above mentioned 30-year period at the Women’s Hospital 99 
of the University Hospital Basel. Data of patients who were diagnosed between 1975 and 1989 100 
were taken from the institutional Gynecologic Cancer registry (index card system). The cases of 101 
the patients who were diagnosed after 1990 were recorded in the institutional prospective 102 
relational web-based database. The median age of these 427 patients at diagnosis was 60 years 103 
(range: 23-91 years).  104 
The study was carried out in accordance with the guidelines of the Ethics Committee of the 105 
University of Basel. 106 
Statistical methods: Statistical differences between ages of different subgroups were analyzed 107 
using the unpaired t-test. Comparisons between nominal parameters were made with the Fisher 108 
exact test. In all statistical tests the level of significance was p<0.05. 109 
 110 
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Results 113 
Out of the entire autopsy cohort of 233 cases, we identified four distinct subgroups (Table 1): 114 
1. Patients with OC diagnosed before autopsy, n=156 (67.0%). 115 
- One hundred thirty-five cases in which the death of the patient was directly due to 116 
OC in its final stage.  117 
- Six patients died within three weeks after primary surgery for OC due to 118 
postoperative complications. 119 
- Fifteen patients had known OC, but had other clearly identifiable causes of death 120 
based on prior clinical evaluation and confirmed by postmortem examination (non-121 
malignant diseases, n=9; other malignant diseases, n=6). 122 
This largest subgroup of the autopsy cohort had a median age at death of 70 years 123 
(range: 24-96 years) and a median DSS of 11 months (range: 1 week-300 months). 124 
2. Patients with OC as an incidental finding, n=16 (6.8%). 125 
In 16 cases, the autopsy reported OC as an incidental finding. The disease was not known 126 
before autopsy and was not the cause of death. Causes of death were as follows: cardiac 127 
disease, n=8; pneumonia, n=3; cerebrovascular disease, n=2; pulmonary embolism, n=1; 128 
sepsis, n=1; acute myeloic leukemia, n=1. The median age at OC diagnosis of these patients 129 
was 80 years (range: 56-92 years).  130 
3. The diagnosis of primary OC at time of autopsy could no longer be upheld after pathologic 131 
review with current histopathological knowledge and techniques, n=24 (10.7%).  132 
In these cases, which had been autopsied between 1975 and 1997, metastatic disease found 133 
during autopsy could be attributed to other primary tumors, and the site of the primaries 134 
could be identified retrospectively (colon, n=10; pancreas, n=5; stomach, n=2; extrahepatic 135 
bile ducts, n=1; cervix uteri, n=3; corpus uteri, n=1; breast, n=1; kidney, n=1). CDX2, CK7, 136 
CK20 and estrogen receptor were the most effective antibodies for discriminating primary 137 
OC from metastases to the ovary. 138 
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The median age of patients with ovarian metastases was 71 years (range: 47–88 years). In 139 
12 of these cases, the patients died from tumor of unknown origin and the misinterpretation 140 
as “ovarian carcinoma” was made at autopsy. In 12 cases, the patient were wrongly 141 
diagnosed with OC while alive and were subsequently treated for this incorrect diagnosis. 142 
4. Patients in whom OC was first diagnosed by autopsy and where death was directly due to 143 
OC in its final stage, n=37 (15.9%). 144 
In these cases, the initial OC diagnosis was made on postmortem examination. Typical 145 
clinical diagnoses were “abdominal tumor of unknown origin”, “progressive cachexia”, or 146 
“suspected pulmonary embolism”. In only four of these 37 cases did the patient die at a 147 
gyneco-oncologic center. The remaining 33 patients died while in care of either the 148 
departments of internal medicine, departments of surgery or nursing homes. These 33 149 
patients with newly diagnosed OC were 81 years old on average and significantly older than 150 
those patients in which the disease was diagnosed and treated during their lifetime by the 151 
local gyneco-oncologic center (60 years, p<0.001).  152 
Table 2 demonstrates the OC incidence data reported by the local gyneco-oncologic center. 153 
It also shows the adjusted OC incidence in that the clinically data and the cases of patients 154 
who died of OC but diagnosis was firstly made by autopsy were grouped together. The 155 
autopsy cases comprised 8.8% of the adjusted OC cohort. The inclusion of the autopsy 156 
cases led to a slight but not significant increase in the median age of the cohort (60 years vs. 157 
62 years, p=0.70). However, the proportion of elderly patients was significantly higher (≥80 158 
years at OC diagnosis: 4.9% vs. 9.3%, p=0.013).  159 
 160 
Discussion 161 
With regard to epidemiology, three distinct subgroups of our autopsy cohort deserve further 162 
attention: 163 
A) Metastatic carcinoma diagnosed as primary OC  164 
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The ovary is a common site of metastases from other primary malignancies; the incidence 165 
of metastatic ovarian tumors has been reported with a wide range of 5-30% of all cancers 166 
occurring in the ovaries [14, 15]. The typical gross and histomorphologic features of these 167 
tumors were first clearly defined in the late 1990s [3-6]. In particular, tumors with a strong 168 
tendency to present in the pelvic cavity may mimic OC both grossly and 169 
histolopathologically. In these difficult and unclear cases, misinterpretation as primary OCs 170 
were formerly not uncommon. In our study cohort, a review of the histopathological slides 171 
showed metastatic tumors in 10% of the cases of our cohort. These cases had been 172 
autopsied between 1975 and 1997. The primary tumor could be identified retrospectively by 173 
applying current histopathological knowledge and also in part by using modern 174 
immunohistochemical methods. Carcinomas of the gastrointestinal tract (75%) were the 175 
most common sources of ovarian metastases mimicking primary OC followed by other 176 
carcinomas of the genital tract (17%). The clinical relevance of these diagnostic pitfalls was 177 
comparatively small. Of the 24 cases in which the clinical and histopathological picture of 178 
ovarian metastases led to the erroneous diagnosis of primary OC, this only had clinical 179 
impact in 12 patients, i.e. the patients ran the risk of receiving an inappropriate therapy. 180 
Our data suggest that incidence and prevalence data of the 1970s-1990s may be adjusted 181 
because up to 10% of carcinomas in the ovary were, in fact, not properly classified. 182 
B) The incidental findings 183 
Previously undiagnosed carcinomas which were incidentally discovered on postmortem 184 
examination in women who died of other causes do not provide information regarding the 185 
incidence of the disease (number of new cases diagnosed in a population during a specific 186 
period) but might be of interest for studying the true prevalence of a disease (the number or 187 
proportion of people who have that disease in a specific period). These latent, asymptomatic 188 
and undetected tumors might be helpful for an improved understanding of carcinogenesis. 189 
In our autopsy cohort, approximately 7% of cases were exactly those cases. 190 
Unlike prostate cancer, which might be considered the most widely discussed malignancy 191 
with a significant gap between incidence and true prevalence of disease [16-18], we do not 192 
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think that the few incidental ovarian carcinoma findings offer new insights into the etiology, 193 
epidemiology or clinical management of OC. We also do not assume that there is a 194 
widespread presence of clinically insignificant disease in OC, as with prostate cancer. A 195 
multitude of autopsy studies on this subject have been published regarding prostate cancer, 196 
only a few on OC [7-12]. Most of these studies evaluated exclusively the metastatic patterns 197 
of the disease at the time of death [7, 9-12]. To our knowledge, our group reported the first 198 
data on latent OC in 2007 (however, these findings were not the actual topic of the previous 199 
paper and thus they were not discussed at that time) [8]. 200 
C) Patients in whom OC was first diagnosed by autopsy and in whom death was directly due to 201 
OC in its final stage  202 
In order to provide an adjusted “real” OC incidence, we believe that these autopsy cases 203 
must be added to those who were diagnosed and treated at the gyneco-oncologic center. The 204 
autopsy sub-cohort (n=34 patients) comprised a distinct subgroup within the OC patients, 205 
namely elderly patients who obviously were judged as being inappropriate for oncological 206 
therapy; in fact, it even seems as if the need for making a correct diagnosis during their 207 
lifetime due to their age and/or condition was not considered important. The inclusion of 208 
these patients did not lead to a significant increase in the median age of OC patients (we 209 
observed only an increase of two years); however, resulted in an almost doubling of the 210 
number of the oldest patients, whom we defined as being ≥80 years of age at the time of OC 211 
diagnosis. These patients were not seen by specialized oncologists and thus play no role in 212 
their perception of the disease; nevertheless, with approximately 7% of the adjusted OC 213 
cohort these cases comprise an important part of the entity “ovarian carcinoma”. 214 
Are our retrospective data important for addressing current or future questions regarding the 215 
etiology of OC? The two following aspects must be considered: 216 
Firstly, geriatric gynecologic oncology is a new field to be explored. In the future, there will 217 
be more tailored and individualized strategies in the oncologic care of elderly patients 218 
which will reflect their functional age [19, 20]. With current standards of anesthesia and 219 
postoperative surveillance, it is possible for many elderly women to safely undergo OC 220 
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surgery, and only a minority of the patients must strictly be categorized as “inoperable” or 221 
“unfit for surgery”. In addition, the chemotherapy situation has changed in such a way that 222 
older women can receive regimens with safer profiles and might derive similar benefits as 223 
their younger counterparts. Progress in the oncologic care of elderly patients will lead to 224 
these patients being treated at gyneco-oncologic centers, and the number of patients in 225 
which the disease is firstly diagnosed at autopsy will decrease. Secondly, autopsy rates have 226 
dramatically decreased in many countries [21-24]. This is also reflected in our autopsy 227 
cohort. From the first decade of the study period (1975-1984), 91 cases were recruited; from 228 
2002 to 2005 only five cases were recruited. Due to the reduced number of autopsies, 229 
important information leading to adjusted prevalence and incidence of OC data will 230 
probably be overlooked [24-27]. 231 
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Tables 313 
Table 1: Four distinct subgroups within the autopsy cohort. 314 
 1. OC known at 
time of autopsy 
2. OC not known 
at time of auto-
psy: incidental 
OC finding 
3. Metastases to 
the ovary (was 
diagnosed as OC 
at autopsy) 
4. OC not known 
at time of auto-
psy: death due to 
OC in final stage 
1975-2005, n=233: 156 16 24 37 
   1975-1984, n=121 
   1985-1994, n=77 
   1995-2005, n=35 
88 (72.7%) 
45 (58.4%) 
23 (68.6%) 
6 (5.0%) 
7 (9.1%) 
3 (8.6%) 
11 (9.1%) 
11 (14.3%) 
2 (5.7%) 
16 (13.2%) 
14 (18.2%) 
7 (20.0%) 
Median age at OC diagnosis 
   (range)     
≥80 years at diagnosis, n=58 
69 years 
(24-96 years) 
25 (43.1%) 
80 years 
(56-92 years) 
9 (15.5%) 
72 years 
(59-88 years) 
2 (3.5%) 
81 years 
(59-98 years) 
22 (37.9%) 
 315 
Table 2: Ovarian carcinoma incidence. 1) Clinically evident incidence only; 316 
2) Adjusted incidence including autopsy data. 317 
 1975-1990 1991-2005 
1) OC diagnosed and treated at the gyneco- 
   oncologic center1 
Median age at OC diagnosis 
 
≥80 years at OC diagnosis 
234 
 
61 years  
(range: 28-83) 
11 (4.7%) 
193 
 
60 years 
(range: 23-91 years) 
10 (5.2%) 
2) OC diagnosed and treated at the gyneco- 
    oncologic center2. 
plus: 
OC firstly diagnosed by autopsy, cause of 
death due to OC3 
Median age at OC diagnosis 
 
≥80 years at OC diagnosis 
 
In total: 
Percentage of patients in whom OC was first 
diagnosed by autopsy  
Median age at OC diagnosis (range) 
≥80 years at OC diagnosis 
231 
 
 
20 
 
81 years  
(range: 59-94) 
11 (55.0%) 
 
251 
8.0% 
 
62 years 
22 (8.8%) 
190 
 
 
13 
 
82 years 
(range: 70-98) 
9 (69.2%) 
 
203 
6.3% 
 
61 years 
20 (9.3%) 
OC: ovarian cancer 318 
1 Included were six cases which were diagnosed and treated at the Basel gyneco-oncologic center during 319 
  this period; however, current pathological review showed that they were not primary OC, but rather 320 
  metastases to the ovaries from other primaries. 321 
2 The above mentioned six cases were excluded from the adjusted incidence model. 322 
3 From the entire autopsy cohort (n=37), we excluded those four patients who died at the gyneco-oncologic center. 323 
 324 
